Skip to main content

Table 1 VRE Sample Demographics (n = 533)

From: VRE in cirrhotic patients

VRE Status
Variable VRE Positive (n = 65) VRE Negative, Gram Negative (n = 80) VRE Negative, Sterile (n = 306)
Age 53.4 (11.1)a 56.2 (10.6) 55.5 (9.7)
Sex
 Male 24 (36.9%) 43 (53.7%) 205 (67.0%)
 Female 41 (63.1%) 37 (46.3%) 101 (33.0%)
Raceb
 White 17 (26.1%) 22 (27.5%) 117 (38.2%)
 African-American 1 (1.5%) 5 (6.3%) 6 (2.0%)
 Hispanic 41 (63.1%) 47 (58.7%) 145 (47.4%)
 Asian 4 (6.2%) 4 (5.0%) 23 (7.5%)
 Other 2 (3.1%) 2 (2.5%) 15 (4.9%)
Child Pugh Scoreb
 A 1 (1.5%) 9 (11.2%) 27 (8.8%)
 B 14 (21.5%) 28 (35.0%) 127 (41.5%)
 C 50 (76.9%) 43 (53.8%) 152 (49.7%)
MELD Scoreb 25.4 (9.9) 20.3 (8.8) 19.7 (9.7)
Culture Siteb
 Blood 12 (18.5%) 20 (43.5%) 62 (49.6%)
 Urine 43 (66.1%) 20 (43.5%) 47 (37.6%)
 Ascitic fluid 4 (6.2%) 4 (8.7%) 14 (11.2%)
 Pleural fluid 0 0 0
 BAL 5 (7.7%) 2 (4.3%) 1 (0.8%)
 Wound 1 (1.5%) 0 1 (0.8%)
Transplant Historyb
 None 48 (73.8%) 62 (77.5%) 238 (78.6%)
 Liver 13 (20.0%) 13 (16.3%) 57 (18.8%)
 Liver/kidney 4 (6.2%) 5 (6.2%) 8 (2.6%)
VRE Treatmentb
 No treatment 12 (19.1%)   
 Linezolid 36 (57.1%)   
 Daptomycin 11 (17.5%)   
 Tigecycline 4 (6.3%)   
  1. aNumbers in table are mean (SD) for age; n (%) for categorical variables
  2. bVRE treatment missing in 2 VRE positive subjects; culture site missing in 34 g negative subjects and in 181 VRE negative, sterile subjects; Meld score missing in 1 VRE negative, sterile subject; transplant history missing in 3 VRE negative, sterile subjects